|
WO2020257333A1
|
|
Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist
|
|
WO2020257336A1
|
|
Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist
|
|
US2020397749A1
|
|
Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist
|
|
WO2020118048A1
|
|
Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist
|
|
WO2020097279A1
|
|
Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose
|
|
US2019262263A1
|
|
Compositions, devices and methods for the treatment of opioid-receptor-mediated conditions
|
|
WO2018064672A1
|
|
Treatment with intranasal naloxone
|
|
MX2018015985A
|
|
Compositions, devices, and methods for the treatment of alcohol use disorder.
|
|
US2017043107A1
|
|
Nasal drug products and methods of their use
|
|
CA2954637A1
|
|
Co-packaged drug products
|
|
EP3777838A1
|
|
Nasal drug products and methods of their use
|
